60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Krystal Biotech Inc (KRYS) stock reached a significant milestone, hitting a 52-week high at 208.29 USD. This marks a notable achievement for the company, which has seen a steady increase in its stock price over the past year. According to InvestingPro data, the stock appears undervalued with an "EXCELLENT" financial health score of 3.87, suggesting further upside potential beyond its current price. The stock's performance reflects a 14.57% increase over the past 12 months, with an even stronger year-to-date return of 26.29%, showcasing the company's growth and resilience in the biotechnology sector. Investors have shown increased confidence in Krystal Biotech's potential, likely influenced by its impressive 94.26% gross profit margin and substantial revenue growth of 54.51% over the last twelve months. InvestingPro offers additional insights through its comprehensive Pro Research Report, one of 1,400+ available for top US equities.
In other recent news, Krystal Biotech Inc. reported a notable earnings beat for the third quarter of 2025. The company's earnings per share (EPS) reached $2.66, significantly surpassing the analysts' forecast of $1.09, marking a surprise of 144.04%. This strong financial performance highlights the company's robust earnings capabilities. Despite this earnings success, the stock experienced a decline in pre-market trading, a move attributed to broader market trends rather than the company's financial health. These recent developments indicate a complex market environment where strong earnings do not necessarily translate to immediate stock gains. Investors may find this juxtaposition of financial performance and stock movement noteworthy. The company's ability to exceed earnings expectations underscores its operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.